Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Abstract

A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

1 . A method of treating medical conditions in a mammal resulting from elevated plasma glucose which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a bicyclo [3.2.1]octan in a double ring system having a basic chemical skeletal of a kaurene structure having the structural formula II:  
       
         
           
           
               
               
           
         
       
       or an analogue, derivative or metabolite thereof, wherein the substance responds in the mammal only at plasma glucose concentrations that are elevated above normal levels.  
     
     
         2 . The method according to  claim 1 , wherein the condition is non-insulin dependent diabetes mellitus, metabolic syndrome, hypertension, or appetite.  
     
     
         3 . The method according to  claim 1 , wherein the response of the bicyclo [3.2.1]octan is initiated by a plasma glucose concentration of 6 mmol/l or greater.  
     
     
         4 . The method according to  claim 1 , wherein the response of the bicyclo [3.2.1]octan is initiated by a plasma glucose concentration of 6 mmol/l or greater.  
     
     
         5 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is selected from the group consisting of steviol, isosteviol, glucosilsteviol, gymnemic acid, steviolbioside, steviosid Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E, Dulcoside A, their pharmaceutically acceptable analogues and their pharmaceutically acceptable derivates.  
     
     
         6 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is isolated from a plant source.  
     
     
         7 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in combination with at least one soy protein or in combination with at least one soy protein and at least one isoflavone.  
     
     
         8 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is present a composition that includes a carrier.  
     
     
         9 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered orally to the mammal and is self-regulating.  
     
     
         10 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to treat non-insulin dependent diabetes mellitus in the mammal.  
     
     
         11 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to treat metabolic syndrome in the mammal.  
     
     
         12 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to stimulate insulin production.  
     
     
         13 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to reduce blood glucagon concentrations in the mammal.  
     
     
         14 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to treat hypertension in the mammal.  
     
     
         15 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to suppress fasting plasma triglycerides in the mammal.  
     
     
         16 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to suppress total cholesterol levels in the mammal.  
     
     
         17 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to act as a dietary supplement.  
     
     
         18 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is administered in an amount effective to act as an appetite suppressant in the mammal.  
     
     
         19 . The method according to  claim 1 , wherein the bicyclo [3.2.1]octan is steviol, isosteviol, glucosilsteviol, gymnemic acid, steviolbioside, stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E or Dulcoside A.